槐耳颗粒联合全身化疗对晚期乳腺癌患者免疫功能及预后的影响

Effects of Huaier Granule Combined with Systemic Chemotherapy on Immunologic Function and Prognosis for Advanced Breast Cancer Patients

目的探讨槐耳颗粒联合全身化疗对晚期乳腺癌患者免疫功能及预后的影响。方法将我院2006年3月至2009年3月期间收治的晚期(Ⅳ期)乳腺癌患者98例按均衡随机化方法随机分为研究组和对照组,对照组仅行单纯全身化疗,研究组给予槐耳颗粒联合全身化疗,槐耳颗粒于化疗开始第1 d同时应用,分别于化疗前1 d及研究实施6个月时检测2组患者外周血T淋巴细胞亚群及IL-2水平,同时观察2组患者3年死亡率和中位生存期。结果化疗前1 d,研究组与对照组CD_4^+、CD_8^+、CD_4^+/CD_8^+T淋巴细胞及IL-2水平比较差异均无统计学意义(P>0.05)。研究实施6个月时,研究组CD_4^+、CD_4^+/CD_8^+T淋巴细胞及IL-2水平明显高于对照组〔CD_4^+:(47.35±6.23)%比(41.33±5.61)%,P<0.05;CD_4^+/CD_8^+:1.84±0.42比1.47±0.33,P<0.05;IL-2水平:(1.78±0.45)μg/L比(1.58±0.30)μg/L,P<0.05〕,CD_8^+T淋巴细胞明显低于对照组〔(23.26±3.25)%比(29.77±4.12)%,P<0.05〕。研究组化疗并发症发生率及3年内死亡率明显低于对照组〔并发症发生率:58.3%(28/48)比86.0%(43/50),P<0.01;3年内死亡率:62.5%(30/48)比82.0%(41/50),P<0.05〕。研究组中位生存期明显长于对照组(33.5个月比24.5个月,P<0.01)。结论从本研究结果初步得出,槐耳颗粒联合全身化疗可以明显提高晚期乳腺癌患者的免疫功能,降低化疗副反应,并改善患者的预后,为中西医结合治疗肿瘤进行有益的探索。

Objective To investigate the effects of Huaier granule combined with systemic chemotherapy on immunologic function and prognosis for advanced breast cancer patients. Methods Ninety-eight cases of IV stage breast cancer from March 2006 to March 2009 in this hospital were divided into control group and research group. Only systemic chemotherapy was performed in the control group, while Huaier granule combined with systemic chemotherapy was applied in the research group, and Huaier granule was given on day 1 systemic chemotherapy start. The changes of T lymphocyte subsets and IL-2 level were detected on day 1 before systemic chemotherapy and on month 6 after Huaier granule combined with systemic chemotherapy. The fatality rate and median survival time were also observed between two groups. Results Compared with the control group, the changes ofT lymphocyte subsets and IL-2 level had no signi- ficant differences on day 1 before systemic chemotherapy between these two groups （P〉0.05）. On month 6 after Huaier granule combined with systemic chemotherapy, the CD4＋, CD4＋/CD8＋ T lymphocyte, and IL-2 level were significantly increased, the CD8＋ T lymphocyte was significantly decreased in the research group as compared with the control group [CD4＋： （47.35±6.23）% versus （41.33±5.61）%, P〈0.05; CD4＋/CD8＋： 1.84±0.42 versus 1.47±0.33, P〈0.05; IL-2 level： （1.78±0.45） μg/L versus （1.58±0.30）μg/L, P〈0.05; CD8＋ （23.26±3.25）% versus （29.77±4.12）%, P〈0.053. The rate of chemotherapy complications and fatality rate within 3 years were significantly decreased in the research group as compared with the control group rate of chemotherapy complications： 58.3% （28/48） versus 86.0% （43/50）, P〈0.01; fatality rate within 3 years： 62.5% （30/48） versus 82.0% （41/50）, P〈0.051. The median survival time in the research group was significantly longer than that in the control group （33.5 months versus 24.5 months, P〈0.01）. Conclusions The preliminary results from this study show that Huaier granule combined with systemic chemotherapy could greatly enhance immune function, reduce side-toxicity of chemotherapy and improve prognosis in advanced breast cancer patients. It provides a beneficial exploration for cancer treatment by integration of traditional and western medicine.